caa a22 4500 465790186 CHVBK 20180323112021.0 cr unu---uuuuu 170327e19900501xx s 000 0 eng 10.1007/BF00177263 doi (NATIONALLICENCE)springer-10.1007/BF00177263 Hypersensitivity reactions to trimetrexate [Elektronische Daten] [Jean Grem, Susan King, Mary Costanza, Thomas Brown] Summary: Trimetrexate is a nonclassical antifol currently being tested for efficacy in cancer patients and as an antiparasitic agent against Pneumocystis carinii pneumonia in AIDS patients. We have now received the first reports of hypersensitivity reactions in Phase II cancer trials. Two types of reactions were noted. The most severe reaction, immediate hypotension with loss of consciousness, occurred in only one patient. Four other patients exhibited an immediate systemic effect with one or more of the following symptoms: facial flushing, fever, shaking, pruritus, bronchospasm, periorbital edema, and difficulty in swallowing. Immediate hypersensitivity should now be considered a known side effect of trimetrexate therapy, occurring in < 2% of patients. Kluwer Academic Publishers, 1990 trimetrexate nationallicence hypersensitivity nationallicence Grem Jean Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD aut King Susan Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD aut Costanza Mary Department of Medicine, Division of Oncology, University of Massachusetts Medical School, Worcester, MA aut Brown Thomas Department of Medicine/Oncology, University of Texas Health Science Center, San Antonio, TX, USA aut Investigational New Drugs Kluwer Academic Publishers 8/2(1990-05-01), 211-214 0167-6997 8:2<211 1990 8 10637 https://doi.org/10.1007/BF00177263 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00177263 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Grem Jean Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD aut NATIONALLICENCE 700 1- King Susan Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD aut NATIONALLICENCE 700 1- Costanza Mary Department of Medicine, Division of Oncology, University of Massachusetts Medical School, Worcester, MA aut NATIONALLICENCE 700 1- Brown Thomas Department of Medicine/Oncology, University of Texas Health Science Center, San Antonio, TX, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/2(1990-05-01), 211-214 0167-6997 8:2<211 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer